TABLE OF CONTENTS 1. INTRODUCTION 32 1.1. OBJECTIVES OF THE STUDY 32 1.2. MARKET DEFINITION 32 1.3. OVERVIEW OF NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET 32 1.4. CURRENCY AND PRICING 33 1.5. LIMITATION 33 1.6. MARKETS COVERED 34 2. MARKET SEGMENTATION 38 2.1. MARKETS COVERED 38 2.2. GEOGRAPHIC SCOPE 40 2.3. YEARS CONSIDERED FOR THE STUDY 41 2.4. CURRENCY AND PRICING 41 2.5. RESEARCH METHODOLOGY 42 2.6. PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 46 2.7. SECONDARY SOURCES 47 2.8. ASSUMPTIONS 47 3. MARKET OVERVIEW 48 3.1. DRIVERS 49 3.1.1. INCREASING PREVALENCE OF CHRONIC DISEASE OR CONDITION 49 3.1.2. GROWING NUMBER OF GERIATRIC POPULATION 49 3.1.3. GROWTH IN DEMAND OF TOPICAL DRUG DELIVERY DRUGS 49 3.1.4. INCREASING INVESTMENT IN RESEARCH AND DEVELOPMENT 50 3.1.5. NEW PRODUCT LAUNCHESBY KEY PLAYERS 50   3.2. RESTRAINTS 50 3.2.1. EXPIRY OF PATENT FOR DRUGS 50 3.2.2. WEAK REIMBURSEMENT POLICIES 50 3.2.3. STRINGENT REGULATORY POLICIES 51 3.3. OPPORTUNITIES 51 3.3.1. HIGH INVESTMENTS IN R&D TO INNOVATE NEW PRODUCTS 51 3.3.2. LUCRATIVE OPPORTUNITIES IN EMERGING MARKET 51 3.3.3. INCREASING MERGERS AND ACQUISITIONS 51 3.4. CHALLENGES 52 3.4.1. PRICING PRESSURE BY GOVERNMENT 52 3.4.2. SIDE EFFECTSOF TOPICAL CORTICOSTEROIDS 53 4. EXECUTIVE SUMMARY 54 5. PREMIUM INSIGHTS 56 6. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY MOLECULE NAME 59 6.1. OVERVIEW 60 6.2. FLUDROXYCORTIDE 62 6.3. TRIAMCINOLONE ACETONIDE 63 6.4. FLUOCINOLONE ACETONIDE 64 6.5. ANTISEPTICS 65 6.6. BETAMETHASONE 66 6.7. CLOBETASONE PROPIONATE 67 6.8. CLOBETASONE BUTYRATE 68 6.9. HALOBETASONE 69 6.10. MOMETASONE 70 6.11. OTHERS 71   7. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY POTENCY CLASS 72 7.1. OVERVIEW 73 7.2. ULTRA HIGH 75 7.2.1. CLOBETASOL PROPIONATE 76 7.2.2. DIFLORASONE DIACETATE 76 7.2.3. BETAMETHASONE DIPROPIONATE GLYCOL 76 7.3. HIGH 77 7.3.1. AMCINONIDE 78 7.3.2. BETAMETHASONE DIPROPIONATE 78 7.3.3. DESOXIMETASONE 78 7.3.4. FLUOCINONIDE 78 7.3.5. OTHERS 79 7.4. MODERATE 79 7.4.1. DESOXIMETASONE 80 7.4.2. FLUOCINOLONE ACETONIDE 80 7.4.3. FLUDROXYCORTIDE 81 7.4.4. HYDROCORTISONE VALERATE 81 7.4.5. TRIAMCINOLONE ACETONIDE 81 7.4.6. CLOBETASONE BUTYRATE 81 7.4.7. OTHERS 81 7.5. MILD 82 7.5.1. HYDROCORTISONE 83 7.5.2. HYDROCORTISONE ACETATE 83 7.5.3. BETAMETHASONE VALERATE 83 7.5.4. DESONIDE 84 7.5.5. FLUOCINOLONE ACETONIDE 84 7.5.6. OTHERS 84   8. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY APPLICATION 85 8.1. OVERVIEW 86 8.2. ACNE 88 8.3. DERMATITIS 89 8.4. PSORIASIS 89 8.5. SKIN INFECTION 91 8.6. HYPERPIGMENTATION 92 8.7. MELASMA 93 8.8. OTHERS 94 9. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY MEDICATION TYPE 95 9.1. OVERVIEW 96 9.2. OINTMENTS 98 9.3. CREAMS 99 9.4. LIQUID & SOLUTIONS 100 9.5. LOTIONS 101 9.6. GEL 102 9.7. OILS 103 9.8. PASTES 104 9.9. SPRAYS 105 9.10. OTHERS 106 10. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY END-USER 107 10.1. OVERVIEW 108 10.2. HOSPITAL 110 10.3. DERMATOLOGY CLINICS 111 10.4. HOMECARE 112 10.5. OTHERS 113   11. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY DISTRIBUTION CHANNEL 114 11.1. OVERVIEW 115 11.2. HOSPITAL PHARMACIES 117 11.3. PHARMACY STORES 118 11.4. ONLINE PHARMACIES 119 11.5. OTHERS 120 12. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY PURCHASE MODE 121 12.1. OVERVIEW 122 12.2. OVER THE COUNTER (OTC) BASED 124 12.3. PRESCRIPTION BASED 125 13. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY BRANDS 126 13.1. OVERVIEW 127 13.2. BETNOVATE 127 13.3. BETNOVATE N 127 13.4. PANDERM PLUS 128 13.5. LOBATE 128 13.6. COSVATE G 128 13.7. CLOP G 128 13.8. TENOVATE GN 128 13.9. LOBATE GM 128 13.10. ULTIDERM 128 13.11. FLUTIVATE 129 13.12. FEXIN 129 13.13. MOMATE 129 13.14. CANDIDERM 129 13.15. OTHERS 129   14. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY GEOGRAPHY 130 14.1. OVERVIEW 131 14.2. NORTH AMERICA 138 14.2.1. U.S. 151 14.2.2. CANADA 156 14.2.3. MEXICO 161 15. NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, COMPANY LANDSCAPE 331 15.1. COMPANY SHARE ANALYSIS: NORTH AMERICA 331 16. COMPANY PROFILES 335 16.1. GLAXOSMITHKLINE PLC. 335 16.1.1. COMPANY OVERVIEW 335 16.1.2. GLAXOSMITHKLINE PLC: REVENUE ANALYSIS 335 16.1.3. PRODUCT PORTFOLIO 336 16.1.4. RECENT DEVELOPMENTS 336 16.2. MERCK & CO. INC. 337 16.2.1. COMPANY OVERVIEW 337 16.2.2. MERCK & CO. INC.: REVENUE ANALYSIS 337 16.2.3. PRODUCT PORTFOLIO 338 16.2.4. RECENT DEVELOPMENTS 338 16.3. LEO PHARMA 339 16.3.1. COMPANY OVERVIEW 339 16.3.2. LEO PHARMA: REVENUE ANALYSIS 339 16.3.3. PRODUCT PORTFOLIO 340 16.3.4. RECENT DEVELOPMENTS 340 16.4. ALMIRALL S.A. 341 16.4.1. COMPANY OVERVIEW 341 16.4.2. ALMIRALL S.A.: COMPANY SNAPSHOT 341 16.4.3. PRODUCT PORTFOLIO 342 16.4.4. RECENT DEVELOPMENTS 342 16.5. VALEANT PHARMACEUTICALS INTERNATIONAL 343 16.5.1. COMPANY OVERVIEW 343 16.5.2. VALEANT PHARMACEUTICALS INTERNATIONAL: REVENUE ANALYSIS 343 16.5.3. PRODUCT PORTFOLIO 344 16.5.4. RECENT DEVELOPMENTS 344 16.6. ZYLERA PHARMACEUTICALS 345 16.6.1. COMPANY OVERVIEW 345 16.6.2. ZYLERA PHARMACEUTICALS: COMPANY SNAPSHOT 345 16.6.3. PRODUCT PORTFOLIO 346 16.6.4. RECENT DEVELOPMENTS 346 16.7. SANDOZ INTERNATIONAL GMBH 347 16.7.1. COMPANY OVERVIEW 347 16.7.2. SANDOZ INTERNATIONAL GMBH: REVENUE ANALYSIS 347 16.7.3. PRODUCT PORTFOLIO 348 16.7.4. RECENT DEVELOPMENTS 348 16.8. PFIZER INC. 349 16.8.1. COMPANY OVERVIEW 349 16.8.2. PFIZER INC.: REVENUE ANALYSIS 349 16.8.3. PRODUCT PORTFOLIO 350 16.8.4. RECENT DEVELOPMENTS 350   16.9. SANOFI S.A. 351 16.9.1. COMPANY OVERVIEW 351 16.9.2. SANOFI S.A.: COMPANY REVENUE ANALYSIS 351 16.9.3. PRODUCT PORTFOLIO 352 16.9.4. RECENT DEVELOPMENTS 352 16.10. ASTRAZENECA 353 16.10.1. COMPANY OVERVIEW 353 16.10.2. ASTRAZENECA: REVENUE ANALYSIS 353 16.10.3. PRODUCT PORTFOLIO 354 16.10.4. RECENT DEVELOPMENTS 354 17. RELATED REPORTS 355

TABLE LIST TABLE 1 PRICE OF VARIOUS PRODUCTS CONTAINING TOPICAL CORTICOSTEROIDS AND ANTIMICROBIALS 52 TABLE 2 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY MOLECULE NAME, 2015– 2024 (USD MILLION) 61 TABLE 3 NORTH AMERICA FLUDROXYCORTIDE MARKET, BY REGION, 2015– 2024 (USD MILLION) 62 TABLE 4 NORTH AMERICA TRIAMCINOLONE ACETONIDE MARKET, BY REGION, 2015– 2024 (USD MILLION) 63 TABLE 5 NORTH AMERICA FLUOCINOLONE ACETONIDE MARKET, BY REGION, 2015– 2024 (USD MILLION) 64 TABLE 6 NORTH AMERICA ANTISEPTICS MARKET, BY REGION, 2015– 2024 (USD MILLION) 65 TABLE 7 NORTH AMERICA BETAMETHASONE MARKET, BY REGION, 2015– 2024 (USD MILLION) 66 TABLE 8 NORTH AMERICA CLOBETASONE PROPIONATE MARKET, BY REGION, 2015– 2024 (USD MILLION) 67 TABLE 9 NORTH AMERICA CLOBETASONE BUTYRATE MARKET, BY REGION, 2015– 2024 (USD MILLION) 68 TABLE 10 NORTH AMERICA HALOBETASONE MARKET, BY REGION, 2015– 2024 (USD MILLION) 69 TABLE 11 NORTH AMERICA MOMETASONE MARKET, BY REGION, 2015– 2024 (USD MILLION) 70 TABLE 12 NORTH AMERICA OTHERS MARKET, BY REGION, 2015– 2024 (USD MILLION) 71 TABLE 13 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY POTENCY CLASS, 2015– 2024 (USD MILLION) 74 TABLE 14 NORTH AMERICA ULTRA HIGH POTENCY TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015-2024 (USD MILLION) 75 TABLE 15 NORTH AMERICA ULTRA HIGH POTENCY CLASS MARKET, BY TYPE, 2015– 2024 (USD MILLION) 76 TABLE 16 NORTH AMERICA HIGH POTENCY TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 77 TABLE 17 NORTH AMERICA HIGH POTENCY CLASS MARKET, BY TYPE, 2015– 2024 (USD MILLION) 78 TABLE 18 NORTH AMERICA MODERATE TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 79 TABLE 19 NORTH AMERICA MODERATE HIGH POTENCY CLASS MARKET, BY TYPE, 2015– 2024 (USD MILLION) 80 TABLE 20 NORTH AMERICA MILD TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 82 TABLE 21 NORTH AMERICA MILD POTENCY CLASS MARKET, BY TYPE, 2015– 2024 (USD MILLION) 83 TABLE 22 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY APPLICATION, 2015 – 2024 (USD MILLION) 87 TABLE 23 NORTH AMERICA ACNE TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 88 TABLE 24 NORTH AMERICA DERMATITIS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 89 TABLE 25 NORTH AMERICA PSORIASIS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 90 TABLE 26 NORTH AMERICA SKIN INFECTION TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 91 TABLE 27 NORTH AMERICA HYPERPIGMENTATION TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 92 TABLE 28 NORTH AMERICA MELASMA TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 93 TABLE 29 NORTH AMERICA OTHERS TOPICAL CORTICOSTEROIDS APPLICATION MARKET, BY REGION, 2015 – 2024 (USD BILLION) 94 TABLE 30 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY MEDICATION TYPE, 2015– 2024 (USD MILLION) 97 TABLE 31 NORTH AMERICA OINTMENT TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015-2024 (USD MILLION) 98 TABLE 32 NORTH AMERICA CREAMS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 99 TABLE 33 NORTH AMERICA LIQUID & SOLUTIONS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 100 TABLE 34 NORTH AMERICA LOTIONS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 101 TABLE 35 NORTH AMERICA GEL TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 102 TABLE 36 NORTH AMERICA OILS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 103 TABLE 37 NORTH AMERICA PASTES TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 104 TABLE 38 NORTH AMERICA SPRAYS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 105 TABLE 39 NORTH AMERICA OTHERS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 106 TABLE 40 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY END-USER, 2015– 2024 (USD MILLION) 109 TABLE 41 NORTH AMERICA HOSPITAL TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 110 TABLE 42 NORTH AMERICA DERMATOLOGY CLINICS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 111 TABLE 43 NORTH AMERICA HOMECARE TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 112 TABLE 44 NORTH AMERICA OTHERS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 113 TABLE 45 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY DISTRIBUTION CHANNEL, 2015– 2024 (USD MILLION) 116 TABLE 46 NORTH AMERICA HOSPITAL PHARMACIES TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 117 TABLE 47 NORTH AMERICA PHARMACY STORES TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 118 TABLE 48 NORTH AMERICA ONLINE PHARMACIES TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 119 TABLE 49 NORTH AMERICA OTHERS TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 120 TABLE 50 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY PURCHASE MODE, 2015– 2024 (USD MILLION) 123 TABLE 51 NORTH AMERICA OVER THE COUNTER (OTC) BASED TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015-2024 (USD MILLION) 124 TABLE 52 NORTH AMERICA PRESCRIPTION BASED TOPICAL CORTICOSTEROIDS MARKET, BY REGION, 2015 – 2024 (USD MILLION) 125 TABLE 53 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY COUNTRY, 2015 – 2024 (USD MILLION) 137 TABLE 54 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY COUNTRY, 2015– 2024 (USD MILLION) 144 TABLE 55 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY MOLECULE NAME, 2015– 2024 (USD MILLION) 145 TABLE 56 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY PURCHASE MODE, 2015– 2024 (USD MILLION) 146 TABLE 57 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY APPLICATION, 2015-2024 (USD MILLION) 147 TABLE 58 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY MEDICATION TYPE, 2015-2024 (USD MILLION) 148 TABLE 59 NORTH AMERICA TOPICAL CORTIOCOSTEROIDS MARKET, BY POTENCY CLASS, 2015– 2024 (USD MILLION) 149 TABLE 60 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY END USER, 2015-2024 (USD MILLION) 149 TABLE 61 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY DISTRIBUTION CHANNEL, 2015-2024 (USD MILLION) 150 TABLE 62 U.S. TOPICAL CORTICOSTEROIDS MARKET, BY MOLECULE NAME, 2015– 2024 (USD MILLION) 151 TABLE 63 U.S. TOPICAL CORTICOSTEROIDS MARKET, BY PURCHASE MODE, 2015– 2024 (USD MILLION) 152 TABLE 64 U.S. TOPICAL CORTICOSTEROIDS MARKET, BY APPLICATION, 2015-2024 (USD MILLION) 152 TABLE 65 U.S. TOPICAL CORTICOSTEROIDS MARKET, BY MEDICATION TYPE, 2015-2024 (USD MILLION) 153 TABLE 66 U.S. TOPICAL CORTIOCOSTEROIDS MARKET, BY POTENCY CLASS, 2015– 2024 (USD MILLION) 154 TABLE 67 U.S. TOPICAL CORTICOSTEROIDS MARKET, BY END USER, 2015-2024 (USD MILLION) 154 TABLE 68 U.S. TOPICAL CORTICOSTEROIDS MARKET, BY DISTRIBUTION CHANNEL, 2015-2024 (USD MILLION) 155 TABLE 69 CANADA TOPICAL CORTICOSTEROIDS MARKET, BY MOLECULE NAME, 2015– 2024 (USD MILLION) 156 TABLE 70 CANADA TOPICAL CORTICOSTEROIDS MARKET, BY PURCHASE MODE, 2015– 2024 (USD MILLION) 157 TABLE 71 CANADA TOPICAL CORTICOSTEROIDS MARKET, BY APPLICATION, 2015-2024 (USD MILLION) 157 TABLE 72 CANADA TOPICAL CORTICOSTEROIDS MARKET, BY MEDICATION TYPE, 2015-2024 (USD MILLION) 158 TABLE 73 CANADA TOPICAL CORTICOSTEROIDS MARKET, BY POTENCY CLASS, 2015– 2024 (USD MILLION) 159 TABLE 74 CANADA TOPICAL CORTICOSTEROIDS MARKET, BY END USER, 2015-2024 (USD MILLION) 159 TABLE 75 CANADA TOPICAL CORTICOSTEROIDS MARKET, BY DISTRIBUTION CHANNEL, 2015-2024 (USD MILLION) 160 TABLE 76 MEXICO TOPICAL CORTICOSTEROIDS MARKET, BY MOLECULE NAME, 2015– 2024 (USD MILLION) 161 TABLE 77 MEXICO TOPICAL CORTICOSTEROIDS MARKET, BY PURCHASE MODE, 2015– 2024 (USD MILLION) 162 TABLE 78 MEXICO TOPICAL CORTICOSTEROIDS MARKET, BY APPLICATION, 2015-2024 (USD MILLION) 163 TABLE 79 MEXICO TOPICAL CORTICOSTEROIDS MARKET, BY MEDICATION TYPE, 2015-2024 (USD MILLION) 164 TABLE 80 MEXICO TOPICAL CORTIOCOSTEROIDS MARKET, BY POTENCY CLASS, 2015– 2024 (USD MILLION) 165 TABLE 81 MEXICO TOPICAL CORTICOSTEROIDS MARKET, BY END USER, 2015-2024 (USD MILLION) 165 TABLE 82 MEXICO TOPICAL CORTICOSTEROIDS MARKET, BY DISTRIBUTION CHANNEL, 2015-2024 (USD MILLION) 166 FIGURES LIST FIGURE 1 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: SEGMENTATION 38 FIGURE 2 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: DATA TRIANGULATION 42 FIGURE 3 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: RESEARCH SNAPSHOT 43 FIGURE 4 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET : BOTTOM UP APPROACH 45 FIGURE 5 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET : TOP DOWN APPROACH 45 FIGURE 6 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: INTERVIEW DEMOGRAPHICS 46 FIGURE 7 NORTH AMERICA IS EXPECTED TO DOMINATE THE MARKET FOR TOPICAL CORTICOSTEROIDS AND ASIA PACIFIC IS EXPECTED TO BE GROWING WITH THE HIGHEST CAGR IN THE FORECAST PERIOD FROM 2017 TO 2024 55 FIGURE 8 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY MOLECULE NAME, SNAPSHOT 2016 60 FIGURE 9 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY POTENCY CLASS, 2016 73 FIGURE 10 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY APPLICATION, 2016 86 FIGURE 11 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY MEDICATION TYPE, 2016 96 FIGURE 12 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY END-USER, 2016 108 FIGURE 13 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY DISTRIBUTION CHANNEL, 2016 115 FIGURE 14 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY PURCHASE MODE, 2016 122 FIGURE 15 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET SNAPSHOT (2016) 132 FIGURE 16 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY GEOGRAPHY (2016) 133 FIGURE 17 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY GROGRAPHY (2017 & 2024) 134 FIGURE 18 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY GEOGRAPHY (2016 & 2024) 135 FIGURE 19 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY MOLECULE NAME (2017 & 2024) 136 FIGURE 20 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET SNAPSHOT (2016) 139 FIGURE 21 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET : BY COUNTRY (2016) 140 FIGURE 22 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: BY COUNTRY (2017 & 2024) 141 FIGURE 23 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET BY COUNTRY (2016 & 2024) 142 FIGURE 24 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET, BY MOLECULE NAME(2017 & 2024) 143 FIGURE 25 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET: COMPANY SHARE 2016 (%) 331 FIGURE 26 NORTH AMERICA TOPICAL CORTICOSTEROIDS MARKET:

• LEO Pharma • Glaxosmithkline Plc, • Pfizer Inc.